A small-scale analysis of genomic mechanisms of acquired resistance in nine patients with previously untreated EGFRm advanced NSCLC who received osimertinib in the Phase I portion of the AURA study showed no cases of acquired EGFR T790M mutation; potential resistance mechanisms identified included other EGFR mutations and amplification of MET and HER216. The gene discussed is MET; the disease is non-small cell lung carcinoma.